Medicare CED’s Possible Link With Expedited Drug Approvals Could Arise At MedCAC Review
This article was originally published in The Pink Sheet Daily
Executive Summary
At its next meeting May 16, the Medicare Evidence Development and Coverage Advisory Committee will hear from former CMS and FDA head Mark McClellan, who has supported the notion of linking Medicare’s coverage with evidence development tool with accelerated drug approvals.